Cargando…

Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results

BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) micros...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonne, Lawrence, Verslype, Chris, Laenen, Annouschka, Cornelissen, Sandra, Deroose, Christophe M., Prenen, Hans, Vandecaveye, Vincent, Van Cutsem, Eric, Maleux, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330173/
https://www.ncbi.nlm.nih.gov/pubmed/28265235
http://dx.doi.org/10.1515/raon-2017-0007
_version_ 1782511210104619008
author Bonne, Lawrence
Verslype, Chris
Laenen, Annouschka
Cornelissen, Sandra
Deroose, Christophe M.
Prenen, Hans
Vandecaveye, Vincent
Van Cutsem, Eric
Maleux, Geert
author_facet Bonne, Lawrence
Verslype, Chris
Laenen, Annouschka
Cornelissen, Sandra
Deroose, Christophe M.
Prenen, Hans
Vandecaveye, Vincent
Van Cutsem, Eric
Maleux, Geert
author_sort Bonne, Lawrence
collection PubMed
description BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. PATIENTS AND METHODS: Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50–100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. RESULTS: A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. CONCLUSIONS: Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered.
format Online
Article
Text
id pubmed-5330173
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-53301732017-03-07 Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results Bonne, Lawrence Verslype, Chris Laenen, Annouschka Cornelissen, Sandra Deroose, Christophe M. Prenen, Hans Vandecaveye, Vincent Van Cutsem, Eric Maleux, Geert Radiol Oncol Research Article BACKGROUND: The aim of the study was to retrospectively evaluate the symptom control, tumour response, and complication rate in patients with liver-predominant metastatic neuroendocrine tumours treated with transarterial chemoembolization using doxorubicin-eluting superabsorbent polymer (SAP) microspheres. PATIENTS AND METHODS: Patients with neuroendocrine liver metastases who underwent hepatic transarterial chemoembolization using doxorubicin-eluting SAP-microspheres (50–100 μm Hepasphere/Quadrasphere Microsphere® particles, Merit Medical, South Jordan, Utah, USA) were included in this study. Pre-and post-procedure imaging studies were evaluated to assess short and intermediate-term tumour response using modified RECIST criteria. Symptom relief and procedure-related complications were evaluated. RESULTS: A total of 27 embolization procedures were performed on 17 patients. Twelve of 17 patients (70%) were symptomatic, including carcinoid syndrome (n = 8) and severe, uncontrollable hypoglycemia (n = 4). Eight of 12 patients (67%) had complete symptom relief, and the remaining 4 (33%) had partial relief. One patient developed ischemic cholecystitis (6%). No other hepatobiliary complications occurred. Short-term and intermediate-term imaging follow-up was available for 15/17 patients (88%) and 12/14 patients (86%) respectively. At short-term follow-up (< 3 months), 14 patients (93%) showed partial response and the remaining patient had progressive disease (7%). At intermediate-term imaging follow-up (> 3 months), partial response, stable disease and progressive disease were found respectively in 7 (58%), 3 (25%) and 2 (17%) patients. CONCLUSIONS: Chemoembolization with doxorubicin-eluting SAP-microspheres is a safe and effective treatment option for neuroendocrine liver metastases and is associated with a low complication rate. In particular, no clinically evident liver necrosis or bile duct complications were encountered. De Gruyter 2017-02-22 /pmc/articles/PMC5330173/ /pubmed/28265235 http://dx.doi.org/10.1515/raon-2017-0007 Text en © 2017 Radiol Oncol
spellingShingle Research Article
Bonne, Lawrence
Verslype, Chris
Laenen, Annouschka
Cornelissen, Sandra
Deroose, Christophe M.
Prenen, Hans
Vandecaveye, Vincent
Van Cutsem, Eric
Maleux, Geert
Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title_full Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title_fullStr Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title_full_unstemmed Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title_short Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
title_sort safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330173/
https://www.ncbi.nlm.nih.gov/pubmed/28265235
http://dx.doi.org/10.1515/raon-2017-0007
work_keys_str_mv AT bonnelawrence safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT verslypechris safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT laenenannouschka safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT cornelissensandra safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT deroosechristophem safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT prenenhans safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT vandecaveyevincent safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT vancutsemeric safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults
AT maleuxgeert safetyandefficacyofdoxorubicinelutingsuperabsorbentpolymermicrospheresforthetreatmentoflivermetastasesfromneuroendocrinetumourspreliminaryresults